Deliver a robust portfolio of drug discovery hit and lead series for leishmaniasis
current phase of drug development
updated 29 Feb 2020
DNDi is searching for chemical compounds with activity against Leishmania parasites. High-throughput screening of diverse compound libraries from pharmaceutical companies, biotechs, and commercial vendors have been completed against Leishmania donovani, in collaboration with screening partners University of Dundee and Institut Pasteur Korea.
Several visceral leishmaniasis active series were identified from GlaxoSmith-Kline’s global compound library screen and progressed through a hit-to-lead programme by DNDi in 2014 in collaboration with the University of Dundee. Furthermore, a screening collaboration agreement with the university signed in December 2014 aims to screen approximately 500,000 compounds against visceral leishmaniasis.
In parallel to its ongoing bilateral collaborations for screening and lead optimization, in 2015 DNDi launched the NTD Drug Discovery Booster with several major pharmaceutical companies.
Get our latest news, personal stories, research articles, and job opportunities.